Source link : https://www.newshealth.biz/health-news/lebrikizumab-found-effective-for-patients-with-ad-soc/
SAN DIEGO — Among patients with skin of color and moderate to severe atopic dermatitis (AD) who underwent 16 weeks of treatment with lebrikizumab, 68% achieved a 75% reduction in the Eczema Area and Severity Index (EASI-75), interim results from a novel phase 3b trial showed. Lebrikizumab, a novel monoclonal antibody being developed by Eli […]
Author : News Health
Publish date : 2024-03-12 20:54:32
Copyright for syndicated content belongs to the linked Source.
in Health